Publications

Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nature communications. 2025. PMID: 41365872

Kayraklioglu N, Zhang L, Cornelia Ding CK, Greenland NY, Stohr BA, Koshkin VS, Simko JP, Sirohi D. Correlation of Lymphocytic Infiltration and Degree of Pleomorphism with Tumor Mutation Burden in High-Grade Urothelial Carcinoma. Human pathology. 2025. PMID: 41354158

Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR. Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. JCO precision oncology. 2025. PMID: 41348987

Iyengar NM, O'Shaughnessy JA, Moore HN, Hamilton E, Jhaveri KL, Ma CX, Tedesco K, Vasekar M, Donahue S, Rugo HS. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. NPJ breast cancer. 2025. PMID: 41345397

Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa D, Melisko M, Chien AJ, Kim MO, Mortimer J, McCann K, Blaes A, Rugo HS. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer. NPJ breast cancer. 2025. PMID: 41339346

Dercle L, Geyer S, Nixon AB, Innocenti F, Shi Q, Jacobson SB, Luk L, Liu A, Yang H, Wen Y, Zhao B, Eche T, Mokrane FZ, Yang M, Meyerhardt J, O'Reilly EM, Venook AP, El-Khoueiry AB, Schwartz LH, Abou-Alfa GK. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). ESMO open. 2025. PMID: 41337859

De Souza AL, Hadfield MJ, Lu S, Golijanin DJ, Wood R, Margolis J, Anderson K, Olszewski AJ, Holder SL, El-Deiry WS, Aggarwal RR, Mega AE, Carneiro BA. BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Cancer Research Communications. 2025. PMID: 41231232

Goretsky Y, Holtzman N, Han S, Reis IM, Suzuki V, Jean P, Mones K, Diaz-Paez M, Benjamin C, Beitinjaneh A, Goodman M, Jimenez AJ, Lekakis L, Pereira D, Spiegel J, Wu Y, Green DJ, Komanduri KV, Wang TP. Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria. Journal of clinical apheresis. 2025. PMID: 41277038

Ko AH. Comprehensive Genomic Profiling for Resectable Pancreatic Cancer: The Earlier the Better? JCO oncology practice. 2025. PMID: 41289544

Chatterjee A, Mustafa Ali MK, Bailey CM, Liu Y, Small D, Smith CC, Traer E, Wang Y, Silvestri G, Baer MR. Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. bioRxiv : the preprint server for biology. 2025. PMID: 41341164

Pithadia DJ, Heskel MJ, Shotayev A, Davda S, Durand R, Cooke D, Czechowicz J, Lesh M, Cornett P, Shimano KA, Mathes EF, Frieden IJ, Apsel Winger B. Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes. Blood vessels, thrombosis & hemostasis. 2025. PMID: 41623364

Vogl UM, Merler S, Angrisani A, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small EJ, Smith MR, Sweeney CJ, Tombal B, Zilli T, Herrmann K, Omlin A, Gillessen S, APCCC 2024 expert panel. A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024. European journal of cancer (Oxford, England : 1990). 2025. PMID: 41407614

Huppert LA, Gliwa AS, Tait M, Quintal L, Starzinski S, Cheung A, Moasser M, Majure M, Melisko M, Munster P, Rugo HS, Campbell M, Fong L, Chien AJ. Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer. NPJ breast cancer. 2025. PMID: 41271741

Corti C, Rugo HS, Tolaney SM. Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 41270251

Celsa C, Pressiani T, Nishida N, Chamseddine SM, Arvind A, Li M, Fortuny M, Khaled NB, Iavarone M, Toyoda H, Rapposelli IG, Casadei-Gardini A, Vivaldi C, Ulahannan S, Andanamala H, Scheiner B, Pinter M, Orlandi E, Fulgenzi CAM, Manfredi GF, Lombardi P, D'Alessio A, Stefanini B, Villani R, Ponziani FR, Stella L, Carminati O, Ricci AD, Gonzalez M, Sparacino A, Di Maria G, Vaccaro M, Cabibbo G, Cammà C, Reig M, Kelley RK, Singal AG, Kaseb AO, Kudo M, Rimassa L, Pinato DJ. Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study. JHEP reports : innovation in hepatology. 2025. PMID: 41675370

Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Matsui Y, Zapatero-Belinchón FJ, McCavitt-Malvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Chen H, Richards AL, Kongpracha P, Bali S, Montano M, Rosecrans J, Matthay M, Togo T, Gonciarz RL, Gopalkrishnan S, Neitz RJ, Krogan NJ, Swaney DL, Shoichet BK, Ott M, Renslo AR, Ashworth A, Fraser JS. The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2. eLife. 2025. PMID: 41258893

Lin Z, Ngo W, Chou YT, Wu H, Susa KJ, Jun YW, Bivona TG, Doudna JA, Wells JA. Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap. Nature chemical biology. 2025. PMID: 41254216

Lin C, Hadfield MJ, Santopietro A, Lagos G, Cheng L, El-Deiry WS, Aggarwal R, Mega A, Hyams E, Carneiro BA. The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer. NPJ precision oncology. 2025. PMID: 41238753

Du J, Wijayaratna UN, Wang X, Fung JP, Huang B, Farzaneh F, Kohn DB, Combes AJ, Gaensler KML. TriLeukeVax: A CD80/IL-15/IL-15Rα Expressing Autologous AML Cell Vaccine Elicits Robust Anti-Leukemic Cytolytic Activity. bioRxiv : the preprint server for biology. 2025. PMID: 41279544

Mulima G, Mody GN, Kaimila B, Salima A, Williams B, Paciorek A, Zhang L, Charles A, Westmoreland KD, Van Loon K, Buckle GC. Treatment Outcomes of Esophageal Cancer in Malawi: An Analysis of Overall Survival and Patient-Reported Outcomes. JCO global oncology. 2025. PMID: 41232057